8 completed, 6 recruiting, 4 unknown, 2 active not recruiting. 14 Phase 2, 5 Phase 3, 3 Phase 1, 2 Not applicable.
Follow Limited Stage Small Cell Lung Cancer: new trials by email Literature Review of Limited Stage Small Cell Lung Cancer trials Research Report on Limited Stage Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer Trilaciclib, Saline (0.9% NaCl) - Limited Stage Small Cell Lung Cancer | Phase 3 | Recruiting | Pharmacosmos A/S | 120 | 2026-09-01 | 2026-10-02 |
| This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer benmelstobart combined with chemotherapy and anlotinib, benmelstobart combined with chemotherapy - Limited Stage Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 66 | 2025-05-20 | 2025-05-18 |
| Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) Probiotics, concurrent Hyperfractionated Radiotherapy, Immunotherapy - Limited Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2025-04-25 | 2026-02-11 |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) BMS-986489, Durvalumab - Limited Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | SCRI Development Innovations, LLC | 250 | 2025-03-11 | 2026-09-21 |
| Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial JS004, Toripalimab, surgery - Limited Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 30 | 2024-04-01 | 2024-05-29 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Tarlatamab, Placebo - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 404 | 2024-02-20 | 2026-04-29 |
| The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy - Limited Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 348 | 2023-08-01 | 2023-05-17 |
| Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Sugemalimab, Placebo - Limited Stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 346 | 2023-07-01 | 2023-08-07 |
| A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy TQB2450 Injection + Anlotinib Hydrochloride Capsules - Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy | Phase 1 | Unknown | Jinming Yu | 20 | 2023-05-30 | 2023-07-12 |
| PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) Prophylactic cranial irradiation - Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer | Not applicable | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 600 | 2022-10-27 | 2026-10-16 |
| Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients HLX10, hypofractionated radiotherapy, Prophylactic Cranial Irradiation (PCI) - Limited Stage Small Cell Lung Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 55 | 2022-09-23 | 2024-05-07 |
| Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy Pamiparib - Limited Stage Small Cell Lung Cancer | Phase 2 | Unknown | Fudan University | 44 | 2022-06-20 | 2022-08-02 |
| Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer Durvalumab - Limited Stage Small Cell Lung Cancer | Phase 2 | Unknown | Beijing Haidian Hospital | 20 | 2021-09-01 | 2021-09-05 |
| Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy - Limited Stage Small Cell Lung Cancer | Phase 2 | Completed | BeiGene | 126 | 2021-07-15 | 2024-10-26 |
| Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy MRI Surveillance, Prophylactic Cranial Irradiation - Limited Stage Small Cell Lung Cancer | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 534 | 2021-04-26 | 2021-04-29 |
| Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Ipilimumab, Nivolumab - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 222 | 2015-12-18 | 2026-08-24 |
| Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients exercise intervention, standard follow-up care, quality-of-life assessment - Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease | Not applicable | Completed | University of Wisconsin, Madison | 21 | 2013-12-01 | 2019-11-18 |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Ponatinib - Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer | Phase 2 | Completed | University of Colorado, Denver | 171 | 2013-09-24 | 2022-02-11 |
| Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer questionnaire administration, quality-of-life assessment, counseling intervention - Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 6 | 2011-01-01 | 2018-08-01 |
| Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer dasatinib - Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2007-04-01 | 2015-05-05 |
Showing 20 of 23. Sign in to see all of them.
Small Cell Lung Carcinoma (10) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (2) · Neoplasms (2) · Adenocarcinoma of Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Neoplasm, Residual (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Tobacco Use Disorder (1)
Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Diseases (10) · Neoplasms by Site (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Neoplasms (9) · Lung Neoplasms (8) · Adenocarcinoma (1) · Carcinoma (1) · Chemically-Induced Disorders (1) · Colonic Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1)
Etoposide (3) · Cisplatin (2) · Drug Therapy (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · durvalumab (2) · AMG 757 (1) · Chemoradiotherapy (1) · Counseling (1) · Dasatinib (1) · Early Intervention, Educational (1) · Glucose (1) · Immunotherapy (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (4) · Fudan University (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Amgen (1) · BeiGene (1) · Beijing Haidian Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · ETOP IBCSG Partners Foundation (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Jinming Yu (1) · Pharmacosmos A/S (1) · SCRI Development Innovations, LLC (1) · Shandong Cancer Hospital and Institute (1) · Sun Yat-sen University (1) · Tang-Du Hospital (1)
China (11) · United States (11) · Belgium (3) · France (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Australia (2) · Austria (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · South Korea (2) · Argentina (1)
Afshin Dowlati (1) · Antonin Levy, MD (1) · Antonius Miller (1) · Corinne Faivre-Finn, MD (1) · Dirk De Ruysscher, MD PhD (1) · Jinming Yu, PhD (1) · Kathryn Weaver (1) · Li Zhang, MD (1) · Melissa Johnson, MD (1) · Nan Bi, Doctor (1) · Quynh-Thu Le (1) · Ross D Camidge, MD, PhD (1) · Samir N. Khleif (1)
PMID 37442748, PMID 38610031, PMID 39146945, PMID 40114144, PMID 40398957, PMID 42763407
2023 (1), P30CA014236 (1), P30CA014520 (1), P30CA043703 (1), U01CA062502 (1), U10CA031946 (1), U10CA032102 (1)